Quality of life and satisfaction with treatment in subjects with type 2 diabetes: results in Spain of the PANORAMA study.
OBJECTIVE
Few studies are available on quality of life and treatment satisfaction of patients with type 2 diabetes mellitus (T2DM). Both of them were the primary objectives of the PANORAMA (NCT00916513) study. Metabolic control, treatment patterns, and management by healthcare professionals were also evaluated.


METHODS
This multicenter, cross-sectional, observational study randomly recruited>40 year-old patients with T2DM from Spanish healthcare centers. HbA1c was measured using the same technique in all patients, who also completed quality of life (EQ-5D and ADDQoL) and treatment satisfaction (DTSQ) questionnaires and the Hypoglycemia Fear Survey (HFS-II).


RESULTS
Fifty-four investigators recruited 751 patients, 60.3% of whom had HbA1c levels <7%. Approximately 25% of patients on monotherapy had HbA1c values ≥ 7%, Patients with longer disease duration and more complex treatments, especially with insulin, showed the poorer control. Despite good overall treatment satisfaction (mean 29.3±6.1, 0 to 36-point scale), patients with a poorer metabolic control, previous hypoglycemia episodes, and more complex therapies had a worse QoL and a greater fear of suffering hypoglycemia.


CONCLUSIONS
Despite advances in metabolic control, there are still areas to improve. Early addition of safe drugs to monotherapy would help achieve control objectives without increasing the risk of hypoglycemia, and delaying the start of insulin therapy. This would also improve QoL and treatment satisfaction.
Departamento de Endocrinología y Metabolismo, Hospital Dr. Negrín, Universidad de Las Palmas, Las Palmas de Gran Canaria, España.
Pedro
P
Depablos-Velasco
Servicio Extremeño de Salud, Centro de Atención primaria de Valdepasillas, Badajoz, España.
Emilio
E
Salguero-Chaves
Servicio Extremeño de Salud, Centro de Atención primaria de Tabara, Zamora, España.
Julio
J
Mata-Poyo
Departamento Médico, AstraZeneca Farmacéutica Spain, S.A., Madrid, España.
Beatriz
B
Derivas-Otero
Departamento Médico, Bristol-Myers Squibb, Madrid, España.
Ricardo
R
García-Sánchez
Departamento Médico, AstraZeneca Farmacéutica Spain, S.A., Madrid, España. Electronic address: Pablo.viguera@astrazeneca.com.
Pablo
P
Viguera-Ester
D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D003430:Cross-Sectional Studies; D048909:Diabetes Complications / Q000453:epidemiology / Q000523:psychology; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000453:epidemiology / Q000523:psychology* / Q000628:therapy; D003927:Diet, Diabetic / Q000523:psychology; D005060:Europe; D005081:Exercise Therapy / Q000523:psychology; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced / Q000209:etiology / Q000523:psychology; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D007328:Insulin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D010349:Patient Compliance; D017060:Patient Satisfaction; D011788:Quality of Life; D012306:Risk; D013030:Spain / Q000453:epidemiology; D011795:Surveys and Questionnaires
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin
Calidad de vida; Diabetes mellitus tipo 2; Quality of life; Satisfacción con el tratamiento; Treatment satisfaction; Type 2 diabetes mellitus